

Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants

Authorised

- Fenbendazole

Product identification

Medicine name:

Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants

Active substance:

Fenbendazole

Target species:

Chicken

Pheasant

Route of administration:

In drinking water use

Product details

Active substance and strength:

Fenbendazole

200.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for use in drinking water

Withdrawal period by route of administration:**In drinking water use:**

-

Chicken

- Eggs. 0 day
- Meat and offal. 8 day * when used at 3 mg fenbendazole / kg bw / day
- Meat and offal. 6 day

-

Pheasant

- Eggs. 0 day
- Meat and offal. 6 day

Do not release pheasants for hunting for at least 6 days after the end of medication.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AC13

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper-evident screw cap with a LDPE sealing disk.

White HDPE canisters with white HDPE ribbed tamper-evident screw cap of 5 litres.

White HDPE canisters with white HDPE ribbed tamper-evident screw cap of 2.5 litres.
White cylindrical High Density Polyethylene (HDPE) bottle with white polypropylene (PP) screw tamper-evident closure of 1 litre.
White cylindrical High Density Polyethylene (HDPE) bottle with white polypropylene (PP) screw tamper-evident closure of 125 ml.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

HuVepharma

Marketing authorisation date:

25/04/2018

Manufacturing sites for batch release:

Biovet AD

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 120198

Date of authorisation status change:

27/01/2022

Reference member state:

Ireland

Procedure number:

IE/V/0579/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia France
Germany Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands
Poland Portugal Romania Slovakia Slovenia Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics